Full course description

About this Course

Precision Medicine For Your Practice is a series of short (20-30 min), online modules covering specific topics in genomics and precision medicine. In this module, Exploring Somatic Cancer Panel Testing, participants will learn about large somatic cancer panels, which test for dozens or hundreds of variants that may be driving cancer growth and suggest therapeutics targeted to the variants that are identified. When should these panels be used? And which patients are good candidates? Learn about benefits, limitations, and challenges of using large somatic cancer panels using the five parts of this module: overview information via an animated video; practice cases to facilitate learning-by-doing; "dig deeper" for more in-depth topics; and logistics and additional resources for more detail.

Disclosures

Release Date: December 20, 2016 
Expiration Date: December 20, 2019 

Objectives
Upon completion of this educational activity, the learner will be able to:

  • Identify the types of clinical information that can be gained from large somatic cancer panels.
  • Determine how large somatic cancer panel results could be applied to patient care.

Target Audience

This activity is designed to meet the educational needs of practicing advanced practice nurses, physicians and physician assistants who provide oncology care.

CNE Approval Statement

The Jackson Laboratory is co-providing this continuing nursing education activity with the American Medical Association and Scripps Translational Science Institute. This continuing nursing education activity was approved by the Northeast Multi-State Division (NE-MSD), an accredited approver by the American Nurses Credentialing Center’s Commission on Accreditation.

Claiming Your Credit
In order to claim credit 1) answer the pre-assessment questions, 2) work through the module content in its entirety, 3) successfully complete the post-assessment answering 2 out of 3 questions correctly and 4) complete the evaluation.   

Nurses are eligible for a maximum of .5 contact hours upon the completion of this activity.

Planning Committee

  • Emily Edelman, MS, CGC, The Jackson Laboratory
  • Abdallah Elias, MD, Shodair Children's Hospital 
  • Therese Ingram Nissen, MA, The Jackson Laboratory
  • Katie Johansen Taber, PhD, American Medical Association
  • Jeanette McCarthy, MPH, PhD, UCSF School of Medicine
  • Laura Nicholson, MD, PhD, Scripps Translational Science Institute 
  • James O'Leary, MBA, Genetic Alliance
  • Kate Reed, MPH, ScM, CGC, The Jackson Laboratory
  • Suzanna Schott, ScM, CGC, The Jackson Laboratory 
  • Janet K. Williams, PhD, RN, FAAN, University of Iowa
Faculty
  • Barry D. Dickinson, PhD, CME Program Committee, AMA (Content Reviewer)
  • Emily Edelman, MS, CGC, Associate Director, Clinical and Continuing Education, The Jackson Laboratory (Author)
  • Abdallah Elias, MD, Department of Medical Genetics, Shodair Children's Hospital (Content Reviewer)
  • Marilyn J. Heine, MD, Hematologist/Oncologists, Regional Hematology Oncology Associates (Content Consultant)
  • Therese Ingram Nissen, MA, Senior Instructional Designer/Technologist, The Jackson Laboratory (Author)
  • Katie Johansen Taber, PhD, Principal Policy Analyst, Science and Biotechnology, AMA (Author)
  • Barbara L. McAneny, MD, CEO, New Mexico Oncology Hematology Consultants (Content Consultant)
  • Laura Nicholson, MD, Co-Director of Education, Scripps Translational Science Institute (Author)
  • James O'Leary, MBA, Chief innovation Officer, Genetic Alliance (Content Reviewer)
  • Kate Reed, MPH, ScM, CGC, Director, Clinical and Continuing Education, The Jackson Laboratory (Author)
  • Suzanna Schott, ScM, CGC, Medical Writer, The Jackson Laboratory (Author)

Conflict of Interest Disclosure

Unless otherwise noted, the program planners and faculty do not have a financial interest/arrangement or affiliation with any organizations that could be perceived as a real or apparent conflict of interest in the context of the subject of this course.

The following disclosures are reported that could be perceived as a real or apparent conflict of interest in the education program:

Jeanette McCarthy, PhD, MPH, consultant to Omica, Inc. and past paid presenter for Illumina, Inc., stockholder of Omica, Inc.

Janet K. Williams, PhD, RN, FAAN, stockholder of Pfizer

In their roles as planners, Dr. McCarthy and Dr. Williams recused themselves from all deliberations relating to content related to the commercial entities with which they have a financial interest and will not be responsible for reviewing for bias the presentation of any faculty who share the same financial interests. All educational material has been peer-reviewed by external reviewers to assess for bias.


References

Damodaran S, Berger MF, Roychowdhury S. Clinical tumor sequencing: opportunities and challenges for precision cancer medicine. Am Soc Clin Oncol Educ Book. 2015:e175-82. http://www.ncbi.nlm.nih.gov/pubmed/25993170

Gingras I, Sonnenblick A, de Azambuja E, et al. The current use and attitudes towards tumor genome sequencing in breast cancer. Sci Rep. 2016. 6:22517 http://www.ncbi.nlm.nih.gov/pubmed/26931736

Gray SW, Hicks-Courant K, Cronin A, Rollins BJ, Weeks JC. Physicians' attitudes about multiplex tumor genomic testing. J Clin Oncol. 2014 May. 32(13):1317-23. http://www.ncbi.nlm.nih.gov/pubmed/24663044

Gray SW, Park ER, Najita J, et al. Oncologists' and cancer patients' views on whole-exome sequencing and incidental findings: results from the CanSeq study. Genet Med. 2016. 18(10):1011-9. http://www.ncbi.nlm.nih.gov/pubmed/26866579

Le Tourneau C, Kamal M, Tsimberidou AM, et al. Treatment Algorithms Based on Tumor Molecular Profiling: The Essence of Precision Medicine Trials. J Natl Cancer Inst. 2015. 108(4). http://www.ncbi.nlm.nih.gov/pubmed/26598514

Levy MA, Lovly CM, Pao W. Translating genomic information into clinical medicine: lung cancer as a paradigm. Genome Res. 2012. 22(11):2101-8. http://www.ncbi.nlm.nih.gov/pubmed/23019146

Marrone M, Filipski KK, Gillanders EM, Schully SD, Freedman AN. Multi-marker Solid Tumor Panels Using Next-generation Sequencing to Direct Molecularly Targeted Therapies. PLoS Curr. 2014. 6. http://www.ncbi.nlm.nih.gov/pubmed/24904755

National Comprehensive Cancer Center. Guidelines for Treatment of Cancer by Site.http://www.nccn.org/professionals/physician_gls/f_guidelines.asp#site

Siegelin MD, Borczuk AC. Epidermal growth factor receptor mutations in lung adenocarcinoma. Lab Invest. 2014. 94(2):129-37. http://www.ncbi.nlm.nih.gov/pubmed/24378644

Subbiah V, Kurzrock R. Universal Genomic Testing Needed to Win the War Against Cancer: Genomics IS the Diagnosis. JAMA Oncol. 2016. 2(6):719-20. http://www.ncbi.nlm.nih.gov/pubmed/27078832

Tannock IF, Hickman JA. Limits to Personalized Cancer Medicine. N Engl J Med. 2016. 375(13):1289-94. http://www.ncbi.nlm.nih.gov/pubmed/27682039

West HJ. No Solid Evidence, Only Hollow Argument for Universal Tumor Sequencing: Show Me the Data. JAMA Oncol. 2016. ;2(6):717-8. http://www.ncbi.nlm.nih.gov/pubmed/27078630

Hardware/software Requirements
Audio speakers or headphones
Screen resolution of 800X600 or higher
Adobe Reader 5.0 or higher 

As of June 4, 2016, we support the following versions of Flash and popular web browsers:

Operating Systems

  • Windows 7 and newer
  • Mac OSX 10.6 and newer
  • Linux - chromeOS

Mobile Operating System Native App Support

  • iOS 7 and newer
  • Android 4.2 and newer
Should you have questions regarding the content of the activity or if you need technical support, please email Clinical and Continuing Education at the Jackson Laboratory.